Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Gregory W. Albers, MD, director, Stanford Stroke Center, Coyote Foundation Professor of Neurology and Neurological Sciences, Stanford Medical Center; and founder, RapidAI. He shared his insight into the development and clinical use of RapidAI, a platform that leverages artificial intelligence to create enhanced, high-quality images from noncontrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion data, aiming to expedient diagnoses, treatment, and transfer decisions Episode Breakdown: 1:15 – Background on RapidAI and its development 3:30 – Findings from the pivotal DIFFUSE clinical program of the system 9:15 – Immediate future plans for RapidAI's capabilities and use 15:55 – Neurology News Minute 18:50 – RapidAI as a complement to the physician in diagnosis 22:00 – Integrating the RapidAI system across the United States 24:50 – The future use of AI in stroke and neuroimaging 28:00 – Closing thoughts The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Lecanemab Rolling Submission for Alzheimer Disease Initiated by Eisai, Biogen Fenfluramine sNDA Submitted for Lennox-Gastaut Syndrome Atogepant Approved for Episodic Migraine Prevention Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

NeurologyLive Mind Moments

48: RapidAI's Effect on Stroke Imaging

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Patricia Bobryk, MHS, PT, MSCS, ATP, physical therapist, UC Health, and cochair, International Organization of MS Rehabilitation Therapists (IOMSRT). Bobryk shared her insight into the clinical care of MS from the perspective of a rehabilitative specialist, and the importance of including physical therapy approaches as part of the multidisciplinary approach to care as early as possible to ensure more beneficial long-term outcomes for patients, also speaking to the latest advances and developments in rehabilitative medicine. Episode Breakdown: 1:55 – Early intervention with rehab therapy  4:00 – The standard care process for rehab in MS 5:55 – The need for more rehabilitation medicine training for MS  8:20 – Underutilized aspects of rehabilitation therapy in comprehensive care 10:20 – Neurology News Minute 14:05 – Patient-reported outcomes and patient priorities in care 15:40 – The comprehensive care model’s effect on rehabilitation efforts  19:00 – Patient education about rehabilitative care 21:45 – Neurologists’ awareness about the importance of physical therapy 23:50 – Tips for neurologists and MS specialists to get patients this care 26:25 – Recent advances in rehabilitative medicine 29:35 – Closing thoughts on the state of care The stories featured in this week's Neurology News Minute are further detailed here: Noncontact Boxing Exercise Assessed for Parkinson Disease Benefit Opicapone Demonstrates Small Benefit for Sleep in Parkinson Disease Amylyx Announces Plans to Submit NDA for AMX0035 for ALS Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

47: Incorporating Physical Therapy Into MS Care

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Deena Kuruvilla, MD, director, Westport Headache Institute, who spoke to the current state of affairs in the clinical care of migraine. She also shared her insight into the issues that specialists need to overcome, such as access to therapy, the real-world use of novel treatments for headache disorders, and the advances that are currently in the research and development stage. Episode Breakdown: 1:25 – Trends in the clinical care of migraine over the last year 5:00 –The effect of the COVID-19 pandemic on patients with migraine 7:05 – Ongoing barriers of access to migraine treatments 9:20 – Neurology News Minute 13:25 –Addressing the need for more migraine specialists 15:55 –Real-world use of available migraine therapies and devices 17:20 – Recent introductions to the physician's migraine toolkit 20:40 – Lingering therapeutic needs in migraine and the role of advocacy in improving care The stories featured in this week's Neurology News Minute are further detailed here: FDA Approves Vivistim VNS System for Ischemic Stroke Motor Deficits FDA Approves Brivaracetam for Partial-Onset Seizures in Pediatric Epilepsy Acute Migraine Treatment INP104 Approved Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

46: Tackling Barriers to Migraine Care

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Adolfo Ramirez-Zamora, MD, associate professor, program director, and chief, Division of Movement Disorders, University of Florida. He detailed the current state of care for patients with advanced Parkinson disease, the ongoing clinical development of therapies, remaining challenges to address in the clinic, and where the field is headed. Episode Breakdown: 2:00 – Overview of the state of care for Parkinson disease 6:00 –The use and importance of patient-reported outcomes 9:20 – Recent advances in the clinical care and research 11:20 – Neurology News Minute 14:10 –The classification of Parkinson disease as a syndrome 15:40 –Ongoing clinical development and biomarker research 20:10 – Improving the education about Parkinson disease The stories featured in this week's Neurology News Minute are further detailed here: FDA Approves Xywav for Idiopathic Hypersomnia AASM Guideline Updates Recommendations for Central Disorders of Hypersomnolence Ravulizumab Phase 3 Trial in ALS Discontinued Due to Lack of Efficacy Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

45: Small Victories: Advancing Care in Parkinson Disease

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Mitchell S.V. Elkind, MD, MS, MPhil, president, American Heart Association/American Stroke Association (AHA/ASA), and chief, division of neurology clinical outcomes research and population sciences, Columbia University. He discussed the AHA/ASA's recent scientific statement outlining the role of primary care physicians in the poststroke phase of care, as well as the recently updated secondary stroke prevention guidelines. The stories feature in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Expanded Data From FIREFISH Published, Risdiplam Continues to Improve SMA Outcomes FDA Accepts Resubmission of Diazepam Buccal Film NDA for Seizure Clusters Dosing of WVE-004 Treatment Begins In Frontotemporal Dementia and ALS Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Kernan WN, Viera AJ, Billinger SA, et al. Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. Published online July 15, 2021. doi: 10.1161/STR.0000000000000382. 2. Kleindorfer DA, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. Stroke. Published online May 24, 2021 doi: 0.1161/STR.0000000000000375

44: AHA/ASA Updates to the Stroke Care Model

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Jessica Zwerling, MD, MS, director of the Montefiore Hudson Valley Center of Excellence for Alzheimer's Disease, to find out more about the role that telehealth may play in the future care of Alzheimer and dementia. She shared her experience with it in the last year and offered insight into how it can affect access and impact social determinants of health. The stories feature in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: NeurologyLive's coverage of the 2021 Alzheimer's Association International Conference Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

43: Is Telehealth Here to Stay for Alzheimer Disease Care?

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Raman Malhotra, MD, associate professor of neurology, Washington University in St. Louis, and president, American Academy of Sleep Medicine (AASM). He discussed the AASM's recent position statement calling for a greater emphasis on sleep health in education, clinical practice, inpatient and long-term care, public health promotion, and the workplace due to sleep's critical role in overall health. He also shared insight into the impact the COVID-19 pandemic has had on sleep and the Healthy People 2030 initiative that the AASM is taking part in. This episode also features a new segment, the Neurology News Minute, which will give you quick updates on the following developments in neurology: NIH Awards Funding to Study RNS System in Lennox-Gastaut Syndrome FDA Commissioner Calls for Independent Review of Agency Interactions on Aducanumab Novel SUDEP-3 Inventory Shows Potential to Predict SUDEP Risk Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE Ramar K, Malhotra RK, Carden KA, et al. Sleep is essential to health: an American Academy of Sleep Medicine position statement. Published online June 21, 2021. doi: 10.5664/jcsm.9476

42: The Importance of Sleep for Overall Health

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Scott D. Newsome, DO, president, Consortium of Multiple Sclerosis Centers (CMSC), director, Neurosciences Consultation and Infusion Center at Green Spring Station, and associate professor of neurology, Johns Hopkins Medicine; and David Li, MD, FRCPC, professor of radiology, associate member in neurology, and director, Multiple Sclerosis/MRI Research Group, University of British Columbia. The pair spoke about the recent consensus guidelines that were published and developed by the Magnetic Resonance Imaging in Multiple Sclerosis study group; the CMSC working group; and the North America Imaging in Multiple Sclerosis MRI Guidelines working group, in partnership, that marked a massive undertaking in the field of MS care. Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. To learn more about the process behind developing these international guidelines, watch our NeurologyLive Peer Exchange: “Updates to the MRI Protocol and Clinical Guidelines for MS: CMSC Working Group.” REFERENCE Wattjes MP, Ciccarelli O, Reich DS, et al; on behalf of the Magnetic Resonance Imaging in Multiple Sclerosis study group, the Consortium of Multiple Sclerosis Centers, and North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. Published online June 14, 2021. doi: 10.1016/S1474-4422(21)00095-8

41: Consensus MRI Guidelines for MS

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Michael J. Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore Medical Center, and professor of neurology, Albert Einstein College of Medicine. He shared his takeaways from the recent SLEEP 2021 meeting, his perspective on the investigational narcolepsy agent FT218, the current pipeline for excessive daytime sleepiness and cataplexy, the pandemic’s impact on sleep care. Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

40: SLEEP 2021: Topline Data, Telemedicine, and Takeaways

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with a number of people in the Alzheimer disease field with varying and nuanced opinions on this decision to better understand not only what this approval means for the clinical care of patients, but what the downstream effects of it may be. Those individuals, in order of appearance, are:  Marwan Sabbagh, MD, director, Cleveland Clinic Lou Ruvo Center for Brain Health, and investigator in the aducanumab trials Anton P. Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program, University of Rochester School of Medicine and Dentistry, and investigator in the aducanumab trials David Knopman, MD, professor of neurology, Mayo Clinic, and investigator in the aducanumab trials Lon Schneider, MD, MS, professor of Psychiatry and the Behavioral Sciences, and Della Martin Chair in Psychiatry and Neuroscience, University of Southern California Keck School of Medicine Robert Howard, MD, MRCPsych, Professor of Old Age Psychiatry, Faculty of Brain Sciences, University College London Ian Kremer, JD, executive director, LEAD Coalition Douglas Scharre, MD, neurologist and director, Division of Cognitive Neurology, Ohio State Wexner Medical Center Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. For more insight and NeurologyLive coverage of aducanumab, click here. 

39: A Controversial FDA Decision

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Barry Hendin, MD, clinical professor, University of Arizona; director, Multiple Sclerosis Clinic, Banner University Medical Center; and chief medical officer, Multiple Sclerosis Association of America. He shared his perspective on the recent World MS Day on May 30, the impact awareness efforts have had on care, and how treatment has evolved during his time as an MS physician. Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

38: Advancing MS Care and Awareness

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Matthew B. Harms, MD, associate professor of neurology, Columbia University, and medical consultant and care center director, Muscular Dystrophy Association. In honor of May as ALS Awareness Month, he detailed the impact that awareness efforts have had on improving patient care and some of the latest research and advances that have been made in amyotrophic lateral sclerosis. Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

37: The Impact of Awareness Efforts in ALS

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Elyse Stock, MD, chief medical officer, Biohaven Pharmaceuticals, and Thomas Shiovitz, MD, director of California Neuroscience Research, to discuss the recently initiated phase 2/3 clinical trial of zavegepant, an oral CGRP-targeting agent for the prevention of migraine developed by Biohaven, as well as how the treatment fits into the gepant class, and the impact that the gepants have had on migraine care overall. Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

36: Zavegepant and the Gepant Class for Migraine Care

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD. Each of them discussed data that they respectively presented at the American Academy of Neurology Annual Meeting. These presentations included novel tools for tracking cognitive decline, analyses of subpopulations of patients with migraine treated with new medicines, the disparities faced by women and Black individuals going through stroke rehabilitation, and more. Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. Check out NeurologyLive's complete coverage of the 2021 American Academy of Neurology Annual Meeting here: neurologylive.com/aan REFERENCES1. Nahas S, Ning X, Cohen JM, Barash S, Campos VR, Silberstein SD. Efficacy of fremanezumab in patients with moderate and higher frequency episodic migraine. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.0462. Nahas S, Jurgens TP, Kessler Y, et al. Cardiovascular safety of fremanezumab in patients with migraine and cardiovascular medical history or risk factors: A pooled analysis of phase 3 studies. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.0343. Cree B, Bennett J, Weinshenker B, et al. Long-term efficacy outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.0764. Cree B, Bennett J, Weinshenker B, et al. Long-term safety outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.1005. Somani S, Nanavati H, Xiaohua Z, Lin C. African American women have lower functional performance during acute inpatient rehabilitation after intracerebral hemorrhagic strokes. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P5 0736. Fernandez H, Odin P, Standaert D, et al. Identifying gaps in Parkinson disease patients eligible for device-aided therapies: results from using the MANAGE-PD tool in patients from G7 countries. Abstract P14.1177. Ontaneda D, Qu J, McGinley M, et al. A Data Driven Approach to Define Disease Course Categories in MS. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.2448. Pila S, Novak M, Weintraub S, et al. The Mobile Toolbox (MBT): A Completely Remote Platform for Cognitive Research. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P7.086

35: Highlights From the AAN Annual Meeting

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Daniel Claassen, MD, MS, director, Huntington’s Disease Clinic, and division chief, Behavioral and Cognitive Neurology, Vanderbilt University Medical Center. He discussed the recent news of trial program terminations from Roche and Wave Life Science and the hope that remains in the Huntington disease pipeline despite these setbacks.  Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

34: Hope and the Huntington Disease Pipeline

"Mind Moments," a podcast from NeurologyLive (https://www.neurologylive.com/), brings you exclusive interviews with experts in neurologic disorders. Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more. For more expert insight into neurology, visit NeurologyLive.com (https://www.neurologylive.com/).

hubhopper

NeurologyLive Mind Moments

hubhopper